IOVANCE BIOTHERAPEUTICS, INC. annual report, FY2013

Business context and reporting period

Registrant and period: The supplied filing is Lion Biotechnologies, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, comparing 2013 with 2012. This does not match the request metadata naming Iovance Biotherapeutics, Inc.; the filing itself identifies Lion Biotechnologies as the registrant.

Lion was a development-stage biotechnology company developing autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy, initially for metastatic melanoma. It had no commercial products or revenue and relied on NIH/NCI research and Lonza for manufacturing development.

Financial performance and position

Gross margin and operating margin are not meaningful because the company had no revenue. The 2013 net loss included $16.66 million of non-cash expense for the Lion acquisition and $2.30 million of non-cash restructuring expense. The common-stockholder loss also included an $8.46 million deemed dividend from the Series A preferred stock’s beneficial conversion feature. By contrast, 2012 results included an $8.64 million non-cash gain from the change in fair value of derivative liabilities.

At December 31, 2013, cash and cash equivalents were $19.67 million, working capital was $17.58 million, and the current ratio was 8.7:1. Total current liabilities were $2.27 million. The company reported no long-term debt; its prior secured and other debt had been converted to equity in the May 2013 restructuring. Stockholders’ equity was $17.60 million, compared with a deficit of $11.32 million in 2012. The 2013 private placement raised $23.29 million gross and approximately $21.8 million net, and included common shares, convertible preferred shares, and warrants.

Material changes versus the prior period

• Net loss increased to $25.38 million from $3.31 million, primarily due to acquisition and restructuring charges and the absence of the prior-year derivative-liability gain.
• Operating expenses fell $1.82 million, mainly because consulting expense declined; research and development expense decreased $0.33 million.
• The May restructuring converted approximately $8.37 million of debt and related obligations to common stock and raised cash, eliminating the reported debt balances.
• The November financing materially improved cash and liquidity, but created substantial potential dilution: 17,000 preferred shares were convertible at an initial $2.00 per common share, and investor and placement-agent warrants covered approximately 12.37 million common shares.
• The company acquired Lion Delaware, changed its name from Genesis Biopharma, and completed a 1-for-100 reverse stock split during 2013.

Outlook, risks, contingencies and unusual items

Management estimated 2014 budgeted spending of $8–10 million, including approximately $5–6 million for research and development, and believed year-end cash could fund planned operations for at least 12 months. The filing also states that the company would need substantial additional financing to complete development and commercialization.

Management targeted a Phase 3 melanoma trial in 2015, subject to FDA agreement, manufacturing-process development and validation, and clinical-site approvals. Manufacturing development was expected to take 12–18 months and cost approximately $3–5 million. The planned Phase 3 trial was estimated to cost at least $30–35 million, treat 300 or more patients, and take at least three years. The company estimated total spending of at least $75–100 million before potential commercial availability and projected a possible BLA filing in 2019, assuming its development assumptions held.

Key risks include uncertain clinical efficacy and regulatory requirements; delays or failure to validate scalable, cGMP-compliant manufacturing; dependence on the NCI, NIH license and Lonza; lack of exclusive licensed technology; competition; and the need for additional capital on acceptable terms. The NIH license includes a 6% royalty on net sales, annual minimum royalties, and contingent milestone payments of up to $6.05 million for melanoma. The five-year CRADA required $1 million annually and could be terminated by either party on 60 days’ notice. The contractual-obligations table reported $3.54 million in scheduled NIH and CRADA payments.

Management concluded disclosure controls were effective, but reported a material weakness in internal control over financial reporting due to insufficient financial-reporting personnel for complex transactions. It described added procedures and an independent consultant to support remediation. The auditor issued an unqualified opinion on the financial statements and did not audit the effectiveness of internal controls. No material legal proceedings were reported.

Most important facts for investors to verify

1. Confirm issuer identity and reporting period: this is Lion Biotechnologies’ 2013 annual report, not an Iovance filing or a standalone fourth-quarter report.
2. Reconcile private-placement proceeds: the filing variously describes net proceeds as approximately $21.8 million and $21.985 million; the audited cash-flow statement reports net financing cash inflows that include other financing transactions.
3. Track cash burn, accrued NIH/NCI obligations, and the timing and terms of any financing needed for later-stage trials.
4. Verify FDA feedback, manufacturing validation progress, trial design, enrollment timing, and whether the company can meet its Phase 3 cost and schedule estimates.
5. Assess dilution from preferred-stock conversion, warrants, equity awards, and future capital raises, as well as progress addressing the material weakness in financial controls.